[This Day] As patients of Chronic Myeloid Leukemia (CML) worldwide celebrate the 10th World CML Day today to raise awareness on a rare haematological disease that represents 15 to 20 per cent of all leukemia in adults and the needs of patients, a non-governmental organisation, Together Maxcare Foundation Nigeria, is pushing for more sensitivity to the plight of patients who have this rare type of leukemia.

Related Links:

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients, Published online: 02 December 2018; doi:10.1038/s41408-018-0125-0Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

Source: Blood Cancer JournalCategory: Hematology Authors: Source Type: research

Adherence to oral chemotherapy is essential for patients with chronic myeloid leukemia (CML) and multiple myeloma (MM) to remain in remission. Few studies have used a Likert-type scale to measure medication ad…

Source: BMC Research NotesCategory: Research Authors: Tags: Research note Source Type: research

Pradeep Kumar, Khaliqur Rahman, Surabhi Kumari, Manish Kumar Singh, Ruchi Gupta, Soniya NityanandJournal of Cancer Research and Therapeutics 2018 14(6):1442-1443

Source: Journal of Cancer Research and TherapeuticsCategory: Cancer & Oncology Authors: Source Type: research

We report a 67-year-old male with PCL which developed while on imatinib mesylate (IM) therapy 38 months after diagnosis of chronic myeloid leukemia (CML). The patient has been treated successfully with bortezomib, melphalan and prednisolone. To our knowledge, only one case of PCL superimposed on Philadelphia positive CML has been reported in the literature and this was before the IM era.

BCR-ABL1 kinase domain mutations are a major mechanism of tyrosine kinase inhibitor (TKI) resistance in patients with chronic myeloid leukemia (CML). These mutations interfere the binding of TKIs to the binding site [1 –3]. To date, various studies have shown that some of these mutations are strongly related to clinical resistance [2–5], and the sensitivity to different TKIs is dependent on the type of mutation [6–10]. Patients with multiple mutations have poorer prognosis than patients with a single mutatio n [11,12].

Source: Leukemia ResearchCategory: Hematology Authors: Tags: Research paper Source Type: research

Conclusion: These results indicate that the level of Ambra1 up-regulation is clearly related to tumorigenesis and progression of BC, probably via influencing several vital pathways. However, this hypothesis needs to be validated with more in-depth experiments in the future.Cell Physiol Biochem 2018;51:1027 –1040

ConclusionsOur work showed that PKI-related ADRs in older patients were similar to those in younger adults, except for vascular ADRs, which were significantly more frequent in the older population. Our results require confirmation by larger studies but could lead physicians to be more vigilant about cardiovascular comorbidities during initiation of PKIs in elderly people.

AbstractA series of indole carboxylic acid conjugates of the podophyllotoxin were synthesized and evaluated as antiproliferative agents against two human chronic myeloid leukemia cell lines. Several compounds (In-2,In-8 andIn-9) not only showed antiproliferative activity against normal K562 cells but also exhibited potent antineoplastic effect against resistant K562/VCR cells. The indole-6-formyl conjugate,In-9, revealed potent cytotoxic activity against K562 and K562/VCR cell lines, with IC50 values of 0.100  ± 0.008 and 0.227 ± 0.011 μM, respectively. Preliminary mechan…

Publication date: Available online 23 November 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Brianna Smith, Michael Savona, Rami S. KomrokjiAbstractMyelodysplastic/Myeloproliferative neoplasms (MDS/MPN) are hybrid group of chronic myeloid neoplasms combining features of both MDS and MPN. The world health organization (WHO) classification coined this group designation in 2008 to include chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomoncoytic leukemia (JMML), refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) as provisional entity, and MDS/MPN…

Abstract
Chronic myeloid leukemia (CML) is a rare hematopoietic stem cell disease that is typically characterized by the abnormal BCR-ABL1 fusion gene on the Philadelphia (Ph) chromosome in neoplastic cells. Dasatinib (Sprycel®) is an orally administered, small molecule tyrosine kinase inhibitor indicated for the treatment of certain hematological malignancies, including Ph-positive CML in the chronic phase (Ph+ CML-CP) in adult and pediatric patients. In open-label phase 1 and phase 2 clinical trials, dasatinib produced early and durable target responses (i.e. molecular, cytogenetic and/or hematologic) in ped…

Source: Paediatric DrugsCategory: Pediatrics Authors: Tags: Paediatr Drugs Source Type: research



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here